Skip to content

US · WVE · BIOTECHNOLOGY

Wave Life Sciences Ltd. (WVE) intrinsic value and stock valuation

$2.56as of 2026-11-21 · Mkt cap 1.2B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Wave Life Sciences Ltd. DCF and intrinsic value

InvestorsCraft values WVE with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from WVE’s statements →

Wave Life Sciences Ltd. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Singapore, CE 018936 wavelifesciences.com

How the business is doing

Fiscal 2013–2025, USD

Revenue
$42.7M+16.3% 5y CAGRd
20132025
Net income
-$-204.38M
20132025
Free cash flow
-$-187.49M
20132025
Total equity
$526.2M+42.2% 5y CAGRd
20132025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2013–2025, USD
20252024202320222021
Revenue$42.7M$108.3M$113.3M$3.65M$41M
Operating income-$-215.38M-$-110.4M-$-68M-$-162.72M-$-127.02M
Net income-$-204.38M-$-97.01M-$-57.51M-$-161.82M-$-122.25M
EPSd-$-1.21M-$-701.55K-$-542.04K-$-2.05M-$-2.36M
Operating cash flow-$-187.49M-$-151.03M-$-19.43M-$-127.78M-$-88.99M
Capital expenditure-$-720K-$-940K-$-1.11M-$-1.36M-$-560K
Free cash flow-$-187.49M-$-151.96M-$-20.55M-$-129.14M-$-89.55M
Total assets$638.5M$352.2M$275M$146.4M$207M
Total debt$17.8M$25.4M$32.1M$37.6M$29.9M
Net debt-$-584.3M-$-276.67M-$-168.23M-$-50.88M-$-120.65M
Total equity$526.2M$209.5M$39.6M-$-45.09M$32.5M
Cash and short-term investments$602.1M$302.1M$200.4M$88.5M$150.6M
Income statement
20252024202320222021
Revenue$42.7M$108.3M$113.3M$3.65M$41M
Cost of revenue$8.85M$0.00$0.00$0.00$0.00
Gross profit$33.9M$108.3M$113.3M$3.65M$41M
Research and development expenses$182.8M$159.7M$130M$115.9M$121.9M
Selling, general and administrative expenses$75.3M$59M$51.3M$50.5M$46.1M
Other expenses-$-8.85M$0.00$0.00$0.00$0.00
Operating expenses$249.3M$218.7M$181.3M$166.4M$168M
Cost and expenses$258.1M$218.7M$181.3M$166.4M$168M
Interest income$10.5M$0.00$0.00$0.00$30K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$8.85M$8.66M$9.21M$10.1M$9.84M
Ebitda-$-195.53M-$-88.34M-$-48.98M-$-151.03M-$-112.61M
Operating income-$-215.38M-$-110.4M-$-68M-$-162.72M-$-127.02M
Total other income/expenses, net$11M$13.4M$9.81M$1.58M$4.57M
Income before tax-$-204.38M-$-97.01M-$-58.19M-$-161.14M-$-122.45M
Income tax expense$0.00$0.00-$-680K$680K-$-200K
Net income-$-204.38M-$-97.01M-$-57.51M-$-161.82M-$-122.25M
Weighted average shares outstanding$168.7M$138.3M$106.1M$78.9M$51.8M
Weighted average diluted shares outstanding$168.7M$138.3M$106.1M$78.9M$51.8M
Balance sheet
20252024202320222021
Cash and short-term investments$602.1M$302.1M$200.4M$88.5M$150.6M
Net receivables$1.28M$1.42M$21.1M$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$614.8M$320.4M$235.4M$98.5M$162.6M
Property, plant and equipment, net$19.9M$28M$35.7M$44.1M$40.6M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$3.81M$0.00$0.00$0.00$0.00
Total non-current assets$23.7M$31.8M$39.6M$47.9M$44.4M
Total assets$638.5M$352.2M$275M$146.4M$207M
Accounts payable$15.7M$16.3M$12.8M$16.9M$7.28M
Short-term debt$8.36M$7.64M$6.71M$5.5M$4.96M
Deferred revenue$44.4M$66M$150.1M$31.6M$37.1M
Total current liabilities$95.1M$111M$186.4M$71.5M$64.2M
Long-term debt$9.4M$17.8M$25.4M$32.1M$25M
Deferred revenue, non-current$7.8M$6.1M$15.6M$79.8M$77.5M
Total non-current liabilities$17.2M$31.7M$48.9M$120M$110.3M
Capital lease obligations$17.8M$25.4M$32.1M$37.6M$29.9M
Total liabilities$112.3M$142.7M$235.3M$191.5M$174.5M
Common stock$1.62B$1.18B$935.4M$802.8M$749.9M
Retained earnings-$-1.33B-$-1.12B-$-1.02B-$-967.34M-$-805.51M
Accumulated other comprehensive income (loss)-$-250K-$-260K-$-120K-$-30K$180K
Total equity$526.2M$209.5M$39.6M-$-45.09M$32.5M
Total investments$3.81M$0.00$0.00$0.00$0.00
Total debt$17.8M$25.4M$32.1M$37.6M$29.9M
Net debt-$-584.3M-$-276.67M-$-168.23M-$-50.88M-$-120.65M
Cash flow statement
20252024202320222021
Net income-$-204.38M-$-97.01M-$-57.51M-$-161.82M-$-122.25M
Depreciation and amortization$8.85M$8.66M$9.21M$10.1M$9.84M
Stock-based compensation$0.00$13.1M$9.79M$17.2M$16.4M
Change in working capital-$-16.94M-$-75.82M$19.1M$6.72M$7.01M
Accounts receivable$150K$19.7M-$-21.09M$0.00$30M
Inventory$0.00$0.00$0.00$0.00$2.04M
Accounts payable-$-560K$3.42M-$-3.76M$9.35M-$-6.57M
Net cash provided by operating activities-$-187.49M-$-151.03M-$-19.43M-$-127.78M-$-88.99M
Investments in property, plant and equipment-$-720K-$-940K-$-1.11M-$-1.36M-$-560K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-720K-$-940K-$-1.11M-$-1.25M-$-560K
Common stock issued$488.2M$236.2M$131.3M$52.3M$55M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$488.2M$253.9M$132.5M$67.2M$55.8M
Net change in cash$300M$101.8M$111.9M-$-62.06M-$-33.93M
Cash at end of period$602.1M$305.8M$204.1M$92.2M$154.2M
Operating cash flow-$-187.49M-$-151.03M-$-19.43M-$-127.78M-$-88.99M
Capital expenditure-$-720K-$-940K-$-1.11M-$-1.36M-$-560K
Free cash flow-$-187.49M-$-151.96M-$-20.55M-$-129.14M-$-89.55M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Wave Life Sciences Ltd.

        Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc-conjugated small interfering RNA designed to silence INHBE mRNA targeting obesity; WVE-008, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of liver disease; WVE-N531, an exon splicing oligonucleotide for the treatment of Duchenne muscular dystrophy; and WVE-003, an allele-selective oligonucleotide for the treatment of Huntington’s disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.

        CEO
        Paul Bolno
        Employees
        317
        Beta
        -1.29

        Explore

        Frequently asked questions

        What is the intrinsic value of Wave Life Sciences Ltd. (WVE)?

        Wave Life Sciences Ltd. (WVE) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is WVE undervalued?

        WVE trades at a price of $2.56 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.